Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease

Fabio Efficace, Franco Mandelli, Paola Fazi, Cristina Santoro, Gianluca Gaidano, Francesco Cottone, Alessandra Borchiellini, Monica Carpenedo, Maria Pina Simula, Valeria Di Giacomo, Micaela Bergamaschi, Iolanda Donatella Vincelli, Francesco Rodeghiero, Marco Ruggeri, Laura Scaramucci, Alessandro Rambaldi, Nicola Cascavilla, Fabio Forghieri, Annamaria Petrungaro, Paolo DitonnoGiovanni Caocci, Sonia Cirrincione, Maria Gabriella Mazzucconi

Research output: Contribution to journalArticle

Abstract

The main objective of this study was to compare health-related quality of life (HRQOL) of primary immune thrombocytopenia (pITP) patients with that of general population, overall, and by patient group (i.e., newly diagnosed, persistent, and chronic patients). Fatigue was also investigated as a secondary objective. Overall, 424 adult patients were enrolled in a multicenter observational study and the control group consisted of a representative sample from the general population. Propensity score matching plus further multivariate linear regression adjustment was used to compare HRQOL outcomes between pITP patients and general population. Mean age of patients was 54 years. Of those with HRQOL assessment, 99 patients (23.6%) were newly diagnosed, 53 (12.6%) were persistent, and 268 (63.8%) were chronic pITP patients. Comparison by patient group versus their respective peers in the general population revealed greater impairments in persistent pITP patients. Persistent pITP patients reported clinically meaningful impairments in physical functioning (−15; 95% CI −24.1 to −5.8; P = 0.002), social functioning (−15.3; 95% CI −25.5 to −5.1; P = 0.004), role physical (−28.4; 95% CI −43.1 to −13.7; P < 0.001), role emotional (−23.9; 95% CI −40.1 to −7.7; P = 0.004), and mental health scales (−11.3; 95% CI −21.2 to −1.4; P = 0.026) of the SF-36 questionnaire. Higher fatigue severity was associated with lower physical and mental HRQOL outcomes. Our findings suggest that the burden of the disease and treatment might depend on the disease phase and that persistent pITP patients are the most vulnerable subgroup. Am. J. Hematol. 91:995–1001, 2016.

Original languageEnglish
Pages (from-to)995-1001
Number of pages7
JournalAmerican Journal of Hematology
Volume91
Issue number10
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Idiopathic Thrombocytopenic Purpura
Fatigue
Quality of Life
Population
Mental Health
Social Adjustment
Propensity Score
Multicenter Studies
Observational Studies
Linear Models

ASJC Scopus subject areas

  • Hematology

Cite this

Efficace, F., Mandelli, F., Fazi, P., Santoro, C., Gaidano, G., Cottone, F., ... Mazzucconi, M. G. (2016). Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. American Journal of Hematology, 91(10), 995-1001. https://doi.org/10.1002/ajh.24463

Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. / Efficace, Fabio; Mandelli, Franco; Fazi, Paola; Santoro, Cristina; Gaidano, Gianluca; Cottone, Francesco; Borchiellini, Alessandra; Carpenedo, Monica; Simula, Maria Pina; Di Giacomo, Valeria; Bergamaschi, Micaela; Vincelli, Iolanda Donatella; Rodeghiero, Francesco; Ruggeri, Marco; Scaramucci, Laura; Rambaldi, Alessandro; Cascavilla, Nicola; Forghieri, Fabio; Petrungaro, Annamaria; Ditonno, Paolo; Caocci, Giovanni; Cirrincione, Sonia; Mazzucconi, Maria Gabriella.

In: American Journal of Hematology, Vol. 91, No. 10, 01.10.2016, p. 995-1001.

Research output: Contribution to journalArticle

Efficace, F, Mandelli, F, Fazi, P, Santoro, C, Gaidano, G, Cottone, F, Borchiellini, A, Carpenedo, M, Simula, MP, Di Giacomo, V, Bergamaschi, M, Vincelli, ID, Rodeghiero, F, Ruggeri, M, Scaramucci, L, Rambaldi, A, Cascavilla, N, Forghieri, F, Petrungaro, A, Ditonno, P, Caocci, G, Cirrincione, S & Mazzucconi, MG 2016, 'Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease', American Journal of Hematology, vol. 91, no. 10, pp. 995-1001. https://doi.org/10.1002/ajh.24463
Efficace, Fabio ; Mandelli, Franco ; Fazi, Paola ; Santoro, Cristina ; Gaidano, Gianluca ; Cottone, Francesco ; Borchiellini, Alessandra ; Carpenedo, Monica ; Simula, Maria Pina ; Di Giacomo, Valeria ; Bergamaschi, Micaela ; Vincelli, Iolanda Donatella ; Rodeghiero, Francesco ; Ruggeri, Marco ; Scaramucci, Laura ; Rambaldi, Alessandro ; Cascavilla, Nicola ; Forghieri, Fabio ; Petrungaro, Annamaria ; Ditonno, Paolo ; Caocci, Giovanni ; Cirrincione, Sonia ; Mazzucconi, Maria Gabriella. / Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. In: American Journal of Hematology. 2016 ; Vol. 91, No. 10. pp. 995-1001.
@article{bfcf98220032445cbc44f879726aa382,
title = "Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease",
abstract = "The main objective of this study was to compare health-related quality of life (HRQOL) of primary immune thrombocytopenia (pITP) patients with that of general population, overall, and by patient group (i.e., newly diagnosed, persistent, and chronic patients). Fatigue was also investigated as a secondary objective. Overall, 424 adult patients were enrolled in a multicenter observational study and the control group consisted of a representative sample from the general population. Propensity score matching plus further multivariate linear regression adjustment was used to compare HRQOL outcomes between pITP patients and general population. Mean age of patients was 54 years. Of those with HRQOL assessment, 99 patients (23.6{\%}) were newly diagnosed, 53 (12.6{\%}) were persistent, and 268 (63.8{\%}) were chronic pITP patients. Comparison by patient group versus their respective peers in the general population revealed greater impairments in persistent pITP patients. Persistent pITP patients reported clinically meaningful impairments in physical functioning (−15; 95{\%} CI −24.1 to −5.8; P = 0.002), social functioning (−15.3; 95{\%} CI −25.5 to −5.1; P = 0.004), role physical (−28.4; 95{\%} CI −43.1 to −13.7; P < 0.001), role emotional (−23.9; 95{\%} CI −40.1 to −7.7; P = 0.004), and mental health scales (−11.3; 95{\%} CI −21.2 to −1.4; P = 0.026) of the SF-36 questionnaire. Higher fatigue severity was associated with lower physical and mental HRQOL outcomes. Our findings suggest that the burden of the disease and treatment might depend on the disease phase and that persistent pITP patients are the most vulnerable subgroup. Am. J. Hematol. 91:995–1001, 2016.",
author = "Fabio Efficace and Franco Mandelli and Paola Fazi and Cristina Santoro and Gianluca Gaidano and Francesco Cottone and Alessandra Borchiellini and Monica Carpenedo and Simula, {Maria Pina} and {Di Giacomo}, Valeria and Micaela Bergamaschi and Vincelli, {Iolanda Donatella} and Francesco Rodeghiero and Marco Ruggeri and Laura Scaramucci and Alessandro Rambaldi and Nicola Cascavilla and Fabio Forghieri and Annamaria Petrungaro and Paolo Ditonno and Giovanni Caocci and Sonia Cirrincione and Mazzucconi, {Maria Gabriella}",
year = "2016",
month = "10",
day = "1",
doi = "10.1002/ajh.24463",
language = "English",
volume = "91",
pages = "995--1001",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease

AU - Efficace, Fabio

AU - Mandelli, Franco

AU - Fazi, Paola

AU - Santoro, Cristina

AU - Gaidano, Gianluca

AU - Cottone, Francesco

AU - Borchiellini, Alessandra

AU - Carpenedo, Monica

AU - Simula, Maria Pina

AU - Di Giacomo, Valeria

AU - Bergamaschi, Micaela

AU - Vincelli, Iolanda Donatella

AU - Rodeghiero, Francesco

AU - Ruggeri, Marco

AU - Scaramucci, Laura

AU - Rambaldi, Alessandro

AU - Cascavilla, Nicola

AU - Forghieri, Fabio

AU - Petrungaro, Annamaria

AU - Ditonno, Paolo

AU - Caocci, Giovanni

AU - Cirrincione, Sonia

AU - Mazzucconi, Maria Gabriella

PY - 2016/10/1

Y1 - 2016/10/1

N2 - The main objective of this study was to compare health-related quality of life (HRQOL) of primary immune thrombocytopenia (pITP) patients with that of general population, overall, and by patient group (i.e., newly diagnosed, persistent, and chronic patients). Fatigue was also investigated as a secondary objective. Overall, 424 adult patients were enrolled in a multicenter observational study and the control group consisted of a representative sample from the general population. Propensity score matching plus further multivariate linear regression adjustment was used to compare HRQOL outcomes between pITP patients and general population. Mean age of patients was 54 years. Of those with HRQOL assessment, 99 patients (23.6%) were newly diagnosed, 53 (12.6%) were persistent, and 268 (63.8%) were chronic pITP patients. Comparison by patient group versus their respective peers in the general population revealed greater impairments in persistent pITP patients. Persistent pITP patients reported clinically meaningful impairments in physical functioning (−15; 95% CI −24.1 to −5.8; P = 0.002), social functioning (−15.3; 95% CI −25.5 to −5.1; P = 0.004), role physical (−28.4; 95% CI −43.1 to −13.7; P < 0.001), role emotional (−23.9; 95% CI −40.1 to −7.7; P = 0.004), and mental health scales (−11.3; 95% CI −21.2 to −1.4; P = 0.026) of the SF-36 questionnaire. Higher fatigue severity was associated with lower physical and mental HRQOL outcomes. Our findings suggest that the burden of the disease and treatment might depend on the disease phase and that persistent pITP patients are the most vulnerable subgroup. Am. J. Hematol. 91:995–1001, 2016.

AB - The main objective of this study was to compare health-related quality of life (HRQOL) of primary immune thrombocytopenia (pITP) patients with that of general population, overall, and by patient group (i.e., newly diagnosed, persistent, and chronic patients). Fatigue was also investigated as a secondary objective. Overall, 424 adult patients were enrolled in a multicenter observational study and the control group consisted of a representative sample from the general population. Propensity score matching plus further multivariate linear regression adjustment was used to compare HRQOL outcomes between pITP patients and general population. Mean age of patients was 54 years. Of those with HRQOL assessment, 99 patients (23.6%) were newly diagnosed, 53 (12.6%) were persistent, and 268 (63.8%) were chronic pITP patients. Comparison by patient group versus their respective peers in the general population revealed greater impairments in persistent pITP patients. Persistent pITP patients reported clinically meaningful impairments in physical functioning (−15; 95% CI −24.1 to −5.8; P = 0.002), social functioning (−15.3; 95% CI −25.5 to −5.1; P = 0.004), role physical (−28.4; 95% CI −43.1 to −13.7; P < 0.001), role emotional (−23.9; 95% CI −40.1 to −7.7; P = 0.004), and mental health scales (−11.3; 95% CI −21.2 to −1.4; P = 0.026) of the SF-36 questionnaire. Higher fatigue severity was associated with lower physical and mental HRQOL outcomes. Our findings suggest that the burden of the disease and treatment might depend on the disease phase and that persistent pITP patients are the most vulnerable subgroup. Am. J. Hematol. 91:995–1001, 2016.

UR - http://www.scopus.com/inward/record.url?scp=84990243932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990243932&partnerID=8YFLogxK

U2 - 10.1002/ajh.24463

DO - 10.1002/ajh.24463

M3 - Article

C2 - 27351715

AN - SCOPUS:84990243932

VL - 91

SP - 995

EP - 1001

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 10

ER -